SEC Form 4 · accession 0001209191-15-063045
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Jul 29, 2015
Accepted (ET)
Jul 31, 2015 · 10:30 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 29, 2015 | M | 10,400 | $35.64 | A | 355,684 | D | |
| Common StockF2,F3 | Jul 29, 2015 | S | 4,000 | $125.71 | D | 351,684 | D | |
| Common StockF3,F4 | Jul 29, 2015 | S | 5,200 | $127.18 | D | 346,484 | D | |
| Common StockF3,F5 | Jul 29, 2015 | S | 1,200 | $127.72 | D | 345,284 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401(k) | |
| Common Stock | holding | — | — | — | 122,700 | I | Common Stock held in trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $35.64 | Jul 29, 2015 | M | 10,400 | D | — | Feb 1, 2016 | Common Stock | 10,400 | 271,200 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $125.71 (range $125.43 to $126.35).
- F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $127.18 (range $126.61 to $127.53).
- F5Open market sales reported on this line occurred at a weighted average price of $127.72 (range $127.62 to $127.97).
- F6Fully vested.